头孢曲松现行剂量对多数危重患儿足够:群体药动学建模与模拟研究
该研究在45例危重患儿中开展群体药动学建模与模拟,评估头孢曲松100 mg/kg每日一次给药的靶标 attainment。结果显示该剂量对敏感病原体(MIC 0.5 mg/L)达标概率为96.8%,但对4×MIC(2 mg/L)仅60.8%;50 mg/kg每日两次方案可分别提高至99.9%和93.4%。
要点
- 现行100 mg/kg每日一次对敏感菌达标良好,但对MIC≥2 mg/L病原体暴露不足。
- eGFR>80 mL/min/1.73 m²或低敏感菌流行区可考虑50 mg/kg每日两次。
- 体重和肾功能是头孢曲松清除率的主要协变量。
核心结论
- 现行头孢曲松100 mg/kg每日一次方案为多数危重患儿提供足够暴露。
- 对eGFR>80 mL/min/1.73 m²或低敏感菌(MIC≥0.5 mg/L)流行区,50 mg/kg每日两次可改善达标率。
研究设计与样本
- 前瞻性群体药动学建模与模拟研究,纳入45例0-18岁危重患儿。
- 给药方案为头孢曲松100 mg/kg每日一次,30分钟静脉输注。
主要发现
- 最终模型为二室模型,体重影响分布容积和清除率,基于肌酐的eGFR额外影响清除率。
- 典型患者(2.5岁,14 kg,eGFR 80 mL/min/1.73 m²)接受100 mg/kg每日一次,对MIC 0.5 mg/L的fT>MIC 100%达标概率为96.8%。
- 同患者对4×MIC(2 mg/L)的达标概率为60.8%。
- 50 mg/kg每日两次方案对MIC 0.5 mg/L和2 mg/L的达标概率分别为99.9%和93.4%。
关键数值与推荐
- 药动学靶标为fT>MIC 100%和fT>4×MIC 100%。
- MIC 0.5 mg/L对应敏感病原体,4×MIC为2 mg/L。
- 推荐对eGFR>80 mL/min/1.73 m²或低敏感菌流行区考虑50 mg/kg每日两次。
临床怎么用
- 多数危重患儿可继续使用100 mg/kg每日一次头孢曲松。
- 对肾功能亢进或低敏感菌感染风险高的患儿,可考虑50 mg/kg每日两次方案。
- 临床决策应结合本地病原菌MIC分布和患儿肾功能评估。
局限性
- 样本量较小(45例),游离浓度样本有限(43份)。
- 研究为单中心设计,外推需谨慎。
- 未报告临床结局数据,仅基于药动学靶标达标概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Ceftriaxone is a cornerstone antibiotic for critically ill children with severe infections. Despite its widespread use, information on the pharmacokinetics of ceftriaxone is lacking in this population. We aimed to determine ceftriaxone pharmacokinetics in critically ill children and to propose ceftriaxone dosing guidelines resulting in adequate target attainment using population pharmacokinetic modeling and simulation. METHODS: Critically ill children (aged 0-18 years) treated with intravenous ceftriaxone (100 mg/kg once daily, infused in 30 minutes) and a central or arterial line in place were eligible. Opportunistic blood sampling for total and unbound ceftriaxone concentrations was used. Population pharmacokinetic analysis was performed using non-linear mixed-effects modeling on NONMEM™ Version 7.4.3. Simulations were performed to select optimal doses using probability of target attainment for two pharmacokinetic targets of the minimum inhibitory concentration (MIC) reflecting the susceptibility of pathogens (f T > MIC 100% and fT > 4 × MIC 100%). RESULTS: Two hundred and five samples for total and 43 time-matched samples for unbound plasma ceftriaxone concentrations were collected from 45 patients, median age 2.5 (range 0.1-16.7) years. A two-compartment model with bodyweight as the co-variate for volume of distribution and clearance, and creatinine-based estimated glomerular filtration rate as an additional covariate for clearance, best described ceftriaxone pharmacokinetics. For a typical patient (2.5 years, 14 kg) with an estimated glomerular filtration rate of 80 mL/min/1.73 m2, the current 100-mg/kg once-daily dose results in a probability of target attainment of 96.8% and 60.8% for a MIC of 0.5 mg/L and 4 × MIC (2 mg/L), respectively, when using fT > MIC 100% as a target. For a 50-mg/kg twice-daily regimen, the probability of target attainment was 99.9% and 93.4%, respectively. CONCLUSIONS: The current dosing regimen of ceftriaxone provides adequate exposure for susceptible pathogens in most critically ill children. In patients with an estimated glomerular filtration rate of > 80 mL/min/1.73 m2 or in areas with a high prevalence of less-susceptible pathogens (MIC ≥ 0.5 mg/L), a twice-daily dosing regimen of 50 mg/kg can be considered to improve target attainment. CLINICAL TRIAL REGISTRATION: POPSICLE study (ClinicalTrials.gov, NCT03248349, registered 14 August, 2017), PERFORM study (ClinicalTrials.gov, NCT03502993, registered 19 April, 2018).
引用
- Hartman SJF, Upadhyay PJ, Hagedoorn NN, et al. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. Clin Pharmacokinet. 2021. PMID: 34036552. doi:10.1007/s40262-021-01035-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。